Vitamin K Fracture Meta-analysis: What the Evidence Says

Quick Answer

Vitamin K Fracture Meta-analysis has 4 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 2 systematic review, 2 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Secondary outcomes included the risk of hip fracture, non-vertebral fracture, vertebral fracture, and falling, as well as the total number of falls. [Massé Olivier (2026); evidence level 1]
• If unpublished data, not obtained through personal communications, were found in another systematic review, we used that review to complete data extraction. [Massé Olivier (2026); evidence level 1]
• The worldwide health organization considers osteoporosis and its associated fragile bone breaks to be two of the most serious public health issues because they affect more than 200 million people who have osteoporosis according to its estimates and women and men above 50 years of age face a lifetime fracture risk that exceeds 50 percent and 20 percent, respectively. [Lv Chen (2026); evidence level 1]
• The economic costs which result from fracture-related health problems create a significant financial burden while they result in extended periods of disability and independence loss and they increase the risk of death which demonstrates that society needs to develop better methods for both preventing and treating these conditions. [Lv Chen (2026); evidence level 1]
• Osteoporosis is a serious bone disease characterized by reduced bone mass and deterioration of the bone microarchitecture, leading to an increased risk of fractures. [Gasser Rudolf Wolfgang (2026); evidence level 3]
• While glucocorticoids (GCs) are assumed to have a bimodal mode of action (increased resorption followed by reduced osteoanabolic activity), other drugs mainly induce increased bone resorption. [Gasser Rudolf Wolfgang (2026); evidence level 3]
• Accumulating evidence indicates that PD is also complicated by osteoporosis and skeletal fragility. [Toussirot Eric (2026); evidence level 3]
• Compared with individuals without PD, patients show lower bone mineral density (BMD) and an increased risk of falls, leading to higher rates of fragility fractures, especially hip fractures. [Toussirot Eric (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For vitamin K fracture meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Massé Olivier (2026). Calcium, vitamin D, or combined supplementation to prevent fractures and falls: systematic review and meta-analysis. DOI: 10.1136/bmj-2025-088050. PMCID: PMC13188451. PMID: 42161415. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13188451/
• Lv Chen (2026). Effects of macro- and micronutrient intake on bone mineral density, osteoporotic fracture risk, inflammation, and functional rehabilitation outcomes in orthopedic patients: a systematic review and meta-analysis. DOI: 10.3389/fnut.2026.1808314. PMCID: PMC13149200. PMID: 42111841. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13149200/
• Gasser Rudolf Wolfgang (2026). Drug-Induced Osteoporosis. DOI: 10.3390/jcm15030993. PMCID: PMC12898846. PMID: 41682673. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12898846/
• Toussirot Eric (2026). Bone health in Parkinson’s disease: a comprehensive review of bone involvement and its pathophysiological mechanisms. DOI: 10.3389/fmed.2025.1737844. PMCID: PMC12835217. PMID: 41608422. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12835217/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.